-
公开(公告)号：EP1503213A2
公开(公告)日：2005-02-02
申请号：EP04077760.9
申请日：1999-08-31
CPC分类号： G01N33/721 , G01N33/6893 , G01N33/92 , G01N2800/32 , G01N2800/323 , G01N2800/324 , Y10S435/967 , Y10S435/973 , Y10S436/809 , Y10S436/819 , Y10T436/104165 , Y10T436/105831
摘要： A method for detecting coronary artery disease for a human patient from the general population and staging the disease, if detected; the method comprising performing the step of testing a sample from the patient for a clinically significant presence of a second marker comprising a malondialdehyde-modified atherogenic protein that is recognized by a scavenger receptor on a macrophage; and performing at least one of the following steps of either testing a sample from the patient for a clinically significant presence of a first marker comprising an oxidized atherogenic protein that is no longer recognized by a low density lipoprotein receptor but is recognized by a scavenger receptor on a macrophage; or testing a sample from the patient for a clinically significant presence of a heart protein; wherein the results from the first step and at least one of the other steps indicates whether the level of the marker in the sample from the individual is clinically significant.
摘要翻译： 一种用于从普通人群中检测人类患者的冠状动脉疾病并检测该疾病的方法，如果检测到的话; 所述方法包括进行测试来自患者的样品以临床上显着存在第二标记的步骤，所述第二标记包含被巨噬细胞上的清道夫受体识别的丙二醛修饰的致动脉粥样化蛋白; 并且执行以下步骤中的至少一个：对来自患者的样品测试临床上显着存在的第一标记物，所述第一标记物包含不再被低密度脂蛋白受体识别但被清道夫受体识别的氧化的致动脉粥样硬化蛋白质 巨噬细胞; 或测试来自患者的样品临床上显着存在的心脏蛋白质; 其中来自第一步骤的结果和至少一个其他步骤指示来自个体的样品中标志物的水平是否在临床上显着。
-
公开(公告)号：EP1503213A3
公开(公告)日：2005-07-13
申请号：EP04077760.9
申请日：1999-08-31
CPC分类号： G01N33/721 , G01N33/6893 , G01N33/92 , G01N2800/32 , G01N2800/323 , G01N2800/324 , Y10S435/967 , Y10S435/973 , Y10S436/809 , Y10S436/819 , Y10T436/104165 , Y10T436/105831
摘要： A method for detecting coronary artery disease for a human patient from the general population and staging the disease, if detected; the method comprising performing the step of testing a sample from the patient for a clinically significant presence of a second marker comprising a malondialdehyde-modified atherogenic protein that is recognized by a scavenger receptor on a macrophage; and performing at least one of the following steps of either testing a sample from the patient for a clinically significant presence of a first marker comprising an oxidized atherogenic protein that is no longer recognized by a low density lipoprotein receptor but is recognized by a scavenger receptor on a macrophage; or testing a sample from the patient for a clinically significant presence of a heart protein; wherein the results from the first step and at least one of the other steps indicates whether the level of the marker in the sample from the individual is clinically significant.
-
搜索结果
2 条记录 (耗时 0.008 秒)
